Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LC-PC02
- Development stage
- Preclinical
- Lead developer
- LISCure Biosciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
LC-PC02 is a preclinical-stage live biotherapeutic product (LBP) being developed by LISCure Biosciences in collaboration with Celltrion for the treatment of Parkinson's disease. As a microbiome-based therapy, LC-PC02 is designed to modulate the gut-brain axis, a critical pathway in the pathogenesis of neurodegenerative disorders. The drug aims to address the underlying mechanisms of Parkinson's, potentially by reducing neuroinflammation or inhibiting the aggregation of alpha-synuclein, though specific molecular targets are often proprietary in early development. The partnership with Celltrion, established in early 2023, leverages LISCure's microbiome platform and Celltrion's manufacturing and clinical development expertise to advance the candidate through proof-of-concept studies.
- Other names
- LC-PC02LC-PC-02LC-PC 02
Beyond the preview
Go deeper on LC-PC02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LC-PC02.